Rabbit monoclonal antibodies (RabMAbs) represent a novel category of immunoreagents that may combine the best properties of both mouse monoclonal antibodies (MMAs) and rabbit antisera. In the attempt to verify the performance of this new class of antibodies
During the last 30 years, there has been increasing interest in mouse monoclonal antibodies (MMAs) over polyclonal antisera (PA) because of their unique properties of uniformity, purity, and indefinite availability. MMAs are generated with the in vitro hybridoma method, originally developed by Kohler et al, 1 that consists of the fusion of spleen cells from an immunized mouse with a nonsecretory murine myeloma cell line. MMAs have been exploited widely and have a fundamental role in diagnostic and, more recently, therapeutic settings. However, it is well known that some immunogens poorly stimulate antibody responses in mice.
On the other hand, PA are characterized by properties different from those generated in mice. Because PA are directed against different epitopes or against several amino acid sequences of an epitope of a given antigen, they tend to exhibit higher affinity than MMAs.
Among several animals, rabbits have been known to produce high titers of high-affinity antibodies, even against antigens that are not immunogenic in mice. [2] [3] [4] [5] [6] Considering that some rabbit PA raised against short synthetic polypeptides often exhibit higher sensitivity than MMAs, it may be that rabbits in general, for unknown reasons, tend to generate higher affinity antibodies to human epitopes.
Theoretically, rabbit monoclonal antibodies (RabMAbs) might combine the best properties of MMAs and the most desirable attributes of rabbit antisera, and, therefore, during the last 20 years, several groups have tried to generate RabMAbs. [6] [7] [8] [9] [10] [11] Because plasmacytomas are unknown in rabbits and rabbit B cells are difficult to transform in vitro with viruses, 7 mouse-rabbit heterohybridomas were generated. 6, [8] [9] [10] However, these heterohybridomas were highly unstable, difficult to clone, and unable to secrete antibodies for a prolonged period. The generation of c-myc/v-abl transgenic rabbits led to the production of rabbit plasmacytoma cell lines that have been used successfully as rabbit fusion partners to create stable rabbit-rabbit hybridomas. 11 Eventually, RabMAbs against cyclin D1 were used successfully in the diagnosis of mantle cell lymphoma. 12 In an attempt to verify the performance of this new class of antibodies on routinely fixed, paraffin-embedded tissue samples, RabMAbs against estrogen receptor (ER), progesterone receptor (PR), Ki-67, cyclin D1, CD3, CD5, CD23, and synaptophysin were tested on a series of several tumor types and on normal tissue. The results were compared with those obtained with classic MMAs against the same antigens.
Materials and Methods
We retrieved 38 cases of breast carcinomas, 12 cases of B-cell chronic lymphocytic lymphoma/leukemia (B-CLL), 12 cases of mantle cell lymphoma (MCL), 6 cases of follicular lymphoma (FL), 8 cases of marginal zone lymphomas (MZL), 2 bone marrow specimens of multiple myeloma (MM), 5 nonneoplastic tonsils, 21 neuronal or neuroendocrine tumors (medulloblastoma, 5; paraganglioma, 1; neuroendocrine carcinoma, 3; small cell lung carcinoma, 12), and 14 non-small cell lung carcinomas (squamous cell carcinoma, 8; adenocarcinoma, 4; bronchioloalveolar carcinoma, 2) from the surgical pathology files of the departments of pathology of the Regional Hospital of Treviso, Treviso, Italy, and the University of Brescia School of Medicine, Brescia, Italy. The 12 B-CLL cases selected for the study included 2 samples from lymph nodes and 10 bone marrow biopsy specimens. The 12 MCL cases (10 of classic type and 2 of blastoid type) included 7 samples from lymph nodes, 3 from bone marrow biopsies, and 2 from gastric biopsies. The MZL cases included 3 samples from spleen and 5 from bone marrow biopsies.
Antigen retrieval (AR) was performed as follows: water bath incubation in EDTA buffer, pH 9, or in citrate buffer, pH 7, for 40 minutes at 98°C; microwave oven incubation at 750 W in 10 mmol/L of citrate buffer, pH 6 or pH 7, for 30 minutes.
Sections from breast carcinomas were immunostained with RabMAbs against ER (clone SP1), PR (clone SP2), and Ki-67 (clone SP6). Sections from the same tumors were immunostained with MMAs against ER (clone 6F11), PR (clone 636), and Ki-67 (clone MIB-1). ER and PR immunostains were also repeated without AR. Data about clones, dilution, AR method, antibody concentration, and source are summarized in ❚Table 1❚.
Sections from 5 normal tonsils and from 12 cases of B-CLL and 12 cases of MCL were immunostained with RabMAbs against CD5 (clone SP19), CD3 (clone SP7), and CD23 (clone SP23). Sections from the same specimens were immunostained with MMAs against CD5 (clone 4C7), CD3 (clone F7.2.38), and CD23 (clone 1B12). Sections from all cases of MCL, B-CLL, MZL, FL, and MM were immunostained with RabMAbs to cyclin D1 (clone SP4) and MMAs to cyclin D1 (clone DCS6).
Sections from 21 neuronal or neuroendocrine neoplasms and 14 non-small cell lung carcinomas, used as control samples, were immunostained with a RabMAb against synaptophysin (clone SP11) and an MMA against the same antigen (clone SY38). All immunostains were performed on an automated immunostainer (DakoCytomation Autostainer, Glostrup, Denmark). Immunohistochemical stains were performed using a sensitive polymer-based detection system (Envision Plus, DakoCytomation). Positivity was indicated by the presence of dark brown nuclear staining for ER, PR, Ki-67, and cyclin D1 and by the presence of cytoplasmic or membrane staining for CD3, CD5, CD23, and synaptophysin. At least 100 tumor cells were considered. The intensity of the staining (graded from 0 to 3+) and the percentage of positive cells were evaluated blindly by 3 investigators (S.R., F.C., and A.P.D.T.).
Results
The results of the comparison of breast cancer markers are summarized in ❚Table 2❚.
ER Immunohistochemical Findings
Both antibodies stained 36 of 38 cases and proved negative in 2 cases. It is interesting that when RabMAb SP1 was used, a mean of 88% positive cells and a mean intensity score of 2.5 were recorded. In contrast, when 6F11 was used, both mean values were lower-percentage of positive cells, 73%; and intensity score, 2.0. Even without AR, the RabMAb SP1 recognized all 36 of 38 positive cases, with a mean percentage of positive cells of 74% and a mean intensity score of 2.0. By contrast, when MMA 6F11 without AR was used, weak positivity was observed in 30 of 38 cases, with a mean value of 18% positive cells ❚Image 1❚.
PR Immunohistochemical Findings
Both antibodies stained 36 of 38 cases and proved negative in 2 cases. No relevant differences were seen in the proportion of the number of positive cells and in the mean intensity score between the 2 MAbs. When AR was not performed, immunopositivity was observed only with the SP2 RabMAb (mean percentage of positive cells, 42%; mean intensity score, 1.5).
Ki-67 Immunohistochemical Findings
The comparison of mean values of Ki-67 positive cells (13% for RabMAb and 11% for MMA) and of the mean intensity scores (2.4 for RabMAb, 2.2 for MMA) showed a modest increase of sensitivity with RabMAb SP6. It is noteworthy that in 2 cases, MIB-1 stained neoplastic cell membranes. This phenomenon was not observed with the RabMAb ❚Image 2❚.
CD3, CD5, and CD23 Immunohistochemical Findings
RabMAbs and MMAs against CD3, CD5, and CD23 showed concordant results. CD3 ❚Image 3❚ and CD5 nicely labeled T lymphocytes in tonsils. As expected, in MCL and B-CLL, the RabMAb against CD5 nicely showed the typical pattern represented by weakly stained neoplastic B cells, in contrast with strongly stained reactive T cells ❚Image 4❚. CD23 stained 12 of 12 cases of B-CLL as expected, whereas all MCL and MZL cases were negative.
Cyclin D1 Immunohistochemical Findings
Of 12 MCL cases, 4, including 1 blastoid-type, were negative with MMA DCS6 and positive with RabMAb SP4 ❚Image 5❚. In 4 of 12 cases, a higher proportion of positive nuclei and a stronger intensity of the staining were detected in sections labeled with SP4. In 4 cases, no major differences were noted between SP4 and DCS6 performance. DCS6 stained a larger number of cells in only 1 case. However, in this case, background staining also was observed. Among the cyclin D1 control group of neoplasms, 2 cases of MM were positive with the RabMAb and MMA, as expected. Conversely, 6 FLs, 10 B-CLLs, and 
Synaptophysin Immunohistochemical Findings
Of 21 cases, 4 (1 medulloblastoma and 3 small cell carcinomas of the lung) were positive with RabMAb SP11 but entirely negative with MMA SY38 ❚Image 6❚. Among the 16 positive concordant cases, a mean percentage of positive cells of 70% and a mean intensity score of 2.0 were observed with RabMAb SP11. By contrast, with the MMA SY38, a mean percentage of positive cells of 46% and a mean intensity score of 1.0 were observed. One case of small cell lung carcinoma did not stain with SP11 or SY38. It is noteworthy that AR did not affect the performance of RabMAb SP11. Among 14 control cases of non-small cell lung carcinoma, the majority were negative with both antibodies. However, 4 and 3 cases were focally positive with SP11 and SY38, respectively. While the percentage of positive cells was similar, the intensity of the staining was stronger with the RabMAb (1.0 for MMA and 2.0 for RabMAb). Synaptophysin immunohistochemical findings are summarized in ❚Table 4❚.
Discussion
During the last 30 years, the technology applied to diagnostic immunohistochemical analysis has focused mostly on the attempt to increase the overall sensitivity of different classes ) and without (B, ×20) antigen retrieval. Mouse monoclonal antibody 6F11 with (C, ×20) and without (D, ×20) antigen retrieval. SP1 exhibits increased sensitivity in both conditions. For proprietary information, see Table 1 of detection systems. [13] [14] [15] [16] [17] [18] The advent of heat-induced AR has permitted dramatic expansion of the number of MAbs suitable for immunohistochemical analysis of formalin-fixed material. 19, 20 The generation of RabMAbs, a new category of immunoreagents, that conjugate the specificity of MMAs with the sensitivity of PA, certainly represents another fundamental step toward the achievement of optimal sensitivity and, consequently, toward improved standardization of diagnostic immunohistochemical procedures.
To verify the performance of this new category of immunoreagents, we tested a panel of commercially available RabMAbs, chosen among the most frequently used products, and compared them with corresponding MMAs.
The determination of ER and PR status in breast cancer represents one of the most important predictive parameters, and its clinical relevance is irrefutable. However, optimal reproducibility still represents an unmatched goal. 21 The comparison of RabMAbs against ER, PR, and Ki-67 in a series of breast carcinomas with the corresponding MMAs clearly demonstrated a significant increase in terms of sensitivity. SP1, in particular, exhibited optimal performance at a dilution 10 times higher than that of 6F11. Acceptable staining was Anatomic Pathology / ORIGINAL ARTICLE A B ❚Image 2❚ Ki-67 labeling with rabbit monoclonal antibody SP6 (A, ×20) overcomes membrane staining rarely observed with MIB-1 (B, ×20). For proprietary information, see Table 1 .
❚Image 3❚ Anti-CD3 SP7 rabbit monoclonal antibody staining pattern in a reactive tonsil (×20).For proprietary information, see Table 1 .
❚Image 4❚ Mantle cell lymphoma immunostained with anti-CD5 rabbit monoclonal antibody SP19. Reactive T cells exhibit stronger staining intensity than neoplastic B cells (×20).For proprietary information, see Table 1 .
obtained with SP1 even in absence of AR, a condition in which 6F11 sensitivity dropped dramatically. PR immunostaining did not show significant differences in terms of percentages of positive cells and staining intensity; nevertheless, the RabMAb allowed a higher working dilution. Ki-67 immunolabeling also is regarded as an important prognostic parameter in a variety of tumors. The comparison between SP6 and MIB-1 showed that the RabMAb tended to stain higher percentages of neoplastic cells. It is interesting that the presence of membrane staining, a phenomenon sometimes observed with the MIB-1 antibody, disappeared when using the SP6 RabMAb. Table 1 .
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❚Image 5❚ In this case of mantle cell lymphoma, the anti-cyclin D1 SP4 rabbit monoclonal antibody labeled most neoplastic cells (A, ×20), whereas the DCS6 mouse monoclonal antibody was completely negative (B, ×20). For proprietary information, see Table 1 .
❚Image 6❚ Small cell lung carcinoma exhibiting strong staining with antisynaptophysin SP11 (without antigen retrieval; A, ×20) and immunonegativity with mouse monoclonal antibody SY38 (B, ×20). For proprietary information, see Table 1 .
Another field in which routine diagnostic immunohistochemical analysis has a fundamental role is represented by the differential diagnosis of small cell non-Hodgkin lymphomas. Traditionally, some of the markers routinely used in this context, such as CD5, CD23, and cyclin D1 in particular, have represented a significant technical challenge. The accurate recognition of MCL relies mainly on the detection of cyclin D1 overexpression. However, the DCS6 MMA always has shown significant limits in sensitivity and reliability. The corresponding RabMAb, SP4, showed optimal sensitivity, also staining cases of MCL that had proved negative with DCS6. Before SP4 became available, the only way to improve the sensitivity of cyclin D1 immunostaining was represented by application of high-pH heat-induced epitope retrieval. 22, 23 However, despite all efforts, Cyclin D1 immunostaining has remained technically challenging. As recently shown by Cheuk and coworkers, 12 the use of RabMAb not only offers higher sensitivity but also permits the use of lower pH buffers, permitting better preservation of cell morphologic features. Regarding CD3, CD5, and CD23, RabMAbs parallel the performance of the corresponding MMAs in specificity. Nevertheless, it is noteworthy that the same results could be achieved at much higher working dilutions.
Synaptophysin represents a widely used neuronal and neuroendocrine marker. Traditionally, synaptophysin is considered specific but not very sensitive, mainly because of poor resistance of epitopes to formalin fixation. SP11 exhibits significantly higher sensitivity for detecting neuroendocrine differentiation in small cell lung carcinomas. It is interesting that the high sensitivity of SP11 made AR totally useless. As far as specificity is concerned, focal synaptophysin staining in a minority of squamous cell carcinomas represented an expected finding, and the same cases also proved positive with the corresponding MMAs.
RabMAbs represent a new category of diagnostic products that when compared with the corresponding MMAs seem to offer increased sensitivity with no apparent loss of specificity. In routine use, they permit higher working dilutions (5 to 10 times on average), permitting significant improvement in laboratory efficiency. The robustness of this new class of immunoreagents also is proved by the fact that in some cases, optimal staining also can be achieved without AR. In consideration of the crucial role of immunohistochemical analysis in the diagnostic setting and in the field of determination of prognostic and predictive parameters, RabMAbs might contribute to achieve better standardization and, consequently, acceptable reproducibility. 21 
